TY - JOUR
T1 - Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer
T2 - ASCO Clinical Practice Guideline Update
AU - Giordano, Sharon H.
AU - Temin, Sarah
AU - Chandarlapaty, Sarat
AU - Crews, Jennie R.
AU - Esteva, Francisco J.
AU - Kirshner, Jeffrey J.
AU - Krop, Ian E.
AU - Levinson, Jennifer
AU - Lin, Nancy U.
AU - Modi, Shanu
AU - Patt, Debra A.
AU - Perlmutter, Jane
AU - Ramakrishna, Naren
AU - Winer, Eric P.
AU - Davidson, Nancy E.
N1 - Publisher Copyright:
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
PY - 2018/9/10
Y1 - 2018/9/10
N2 - Purpose To update evidence-based guideline recommendations for practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer to 2018. Methods An Expert Panel conducted a targeted systematic literature review (for both systemic treatment and CNS metastases) and identified 622 articles. Outcomes of interest included overall survival, progression-free survival, and adverse events. Results Of the 622 publications identified and reviewed, no additional evidence was identified that would warrant a change to the 2014 recommendations. Recommendations HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis. Trastuzumab, pertuzumab, and taxane for first-line treatment and trastuzumab emtansine for second-line treatment are recommended. In the third-line setting, clinicians should offer other HER2-targeted therapy combinations or trastuzumab emtansine (if not previously administered) and may offer pertuzumab if the patient has not previously received it. Optimal duration of chemotherapy is at least 4 to 6 months or until maximum response, depending on toxicity and in the absence of progression. HER2-targeted therapy can continue until time of progression or unacceptable toxicities. For patients with HER2-positive and estrogen receptor–positive/progesterone receptor–positive breast cancer, clinicians may recommend either standard first-line therapy or, for selected patients, endocrine therapy plus HER2-targeted therapy or endocrine therapy alone. Additional information is available at www.asco.org/breast-cancer-guidelines.
AB - Purpose To update evidence-based guideline recommendations for practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer to 2018. Methods An Expert Panel conducted a targeted systematic literature review (for both systemic treatment and CNS metastases) and identified 622 articles. Outcomes of interest included overall survival, progression-free survival, and adverse events. Results Of the 622 publications identified and reviewed, no additional evidence was identified that would warrant a change to the 2014 recommendations. Recommendations HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis. Trastuzumab, pertuzumab, and taxane for first-line treatment and trastuzumab emtansine for second-line treatment are recommended. In the third-line setting, clinicians should offer other HER2-targeted therapy combinations or trastuzumab emtansine (if not previously administered) and may offer pertuzumab if the patient has not previously received it. Optimal duration of chemotherapy is at least 4 to 6 months or until maximum response, depending on toxicity and in the absence of progression. HER2-targeted therapy can continue until time of progression or unacceptable toxicities. For patients with HER2-positive and estrogen receptor–positive/progesterone receptor–positive breast cancer, clinicians may recommend either standard first-line therapy or, for selected patients, endocrine therapy plus HER2-targeted therapy or endocrine therapy alone. Additional information is available at www.asco.org/breast-cancer-guidelines.
UR - http://www.scopus.com/inward/record.url?scp=85051377925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051377925&partnerID=8YFLogxK
U2 - 10.1200/JCO.2018.79.2697
DO - 10.1200/JCO.2018.79.2697
M3 - Article
C2 - 29939838
AN - SCOPUS:85051377925
SN - 0732-183X
VL - 36
SP - 2736
EP - 2740
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 26
ER -